Elmind Capital, LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$403.8M2026 Q3
Positions30
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.65.1%
What Changed This Quarter?
Top Holdings
CLDX
Celldex Therapeutics
8.9%
LEGN
Legend Biotech
7.7%
SNDX
Syndax Pharmaceuticals
7.5%
COGT
Cogent Biosciences
6.9%
RLAY
Relay Therapeutics
6.5%
AMLX
Amylyx Pharmaceuticals
6.4%
VRDN
Viridian Therapeutics
6.2%
PCVX
Vaxcyte
5.2%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.